Skip to content

Study · Animal study (in vivo) · rat · 2009

6 results

NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats.

Lu XC, Si Y, Williams AJ, Hartings JA, Gryder D, Tortella FC

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism29 Jul 2009Cited by 27 (Europe PMC)

PMID19638995 (opens in a new tab)DOI10.1038/jcbfm.2009.109 (opens in a new tab)PepBankPUB-19638995
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, NNZ-2566 before seizure onset reduced NCS incidence to 36%-80%, versus 91% with saline.

    In plain wordsIn rats with stroke, NNZ-2566 before seizures reduced seizure incidence versus saline.

    Peptide
    Trofinetide
    Outcome
    DecreaseNCS incidence with early treatment
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    3, 10, or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    When NNZ-2566 was administered before the NCS events, it dose-dependently reduced the NCS incidence to 36%-80%, decreased NCS frequency to 5-16 episodes per rat, and shortened the total duration of NCS to 251-706 secs per rat.
    4 context sentences
    Summary · context
    The results revealed that 91% of the saline-treated animals had NCSs (23 episodes per rat and 1238 secs per rat) with an onset latency of 35 mins after injury.
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, early NNZ-2566 reduced NCS frequency to 5-16 episodes per rat, versus 23 with saline.

    In plain wordsIn rats with stroke, early NNZ-2566 reduced seizure frequency versus saline.

    Peptide
    Trofinetide
    Outcome
    DecreaseNCS frequency with early treatment
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    3, 10, or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    When NNZ-2566 was administered before the NCS events, it dose-dependently reduced the NCS incidence to 36%-80%, decreased NCS frequency to 5-16 episodes per rat, and shortened the total duration of NCS to 251-706 secs per rat.
    4 context sentences
    Summary · context
    The results revealed that 91% of the saline-treated animals had NCSs (23 episodes per rat and 1238 secs per rat) with an onset latency of 35 mins after injury.
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, early NNZ-2566 shortened NCS duration to 251-706 secs per rat, versus 1238 with saline.

    In plain wordsIn rats with stroke, early NNZ-2566 shortened seizure duration versus saline.

    Peptide
    Trofinetide
    Outcome
    DecreaseNCS duration with early treatment
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    3, 10, or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    When NNZ-2566 was administered before the NCS events, it dose-dependently reduced the NCS incidence to 36%-80%, decreased NCS frequency to 5-16 episodes per rat, and shortened the total duration of NCS to 251-706 secs per rat.
    4 context sentences
    Summary · context
    The results revealed that 91% of the saline-treated animals had NCSs (23 episodes per rat and 1238 secs per rat) with an onset latency of 35 mins after injury.
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, the two high NNZ-2566 doses significantly reduced infarct volume by 28%-30%.

    In plain wordsIn rats with stroke, the two high NNZ-2566 doses reduced infarct volume versus saline.

    Peptide
    Trofinetide
    Outcome
    DecreaseInfarct volume with early high doses
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    The two high doses significantly reduced the infarct volume by 28%-30%.
    3 context sentences
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, NNZ-2566 after the first NCS event attenuated NCS duration versus saline.

    In plain wordsIn rats with stroke, delayed NNZ-2566 shortened seizure duration versus saline.

    Peptide
    Trofinetide
    Outcome
    DecreaseNCS duration with delayed treatment
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    3, 10, or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    Delayed treatment also attenuated NCS duration but had no effect on the infarct volume.
    3 context sentences
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with pMCAo, delayed NNZ-2566 had no effect on infarct volume versus saline.

    In plain wordsIn rats with stroke, delayed NNZ-2566 did not affect infarct volume versus saline.

    Peptide
    Trofinetide
    Outcome
    No significant changeInfarct volume with delayed treatment
    Study

    ratn: not reported in source

    Permanent middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    3, 10, or 100 mg/kg bolus followed by 3 mg/kg per hour · 12 hAs given in this study (rat).

    Source sentences

    Summary
    Delayed treatment also attenuated NCS duration but had no effect on the infarct volume.
    3 context sentences
    Summary · context
    Continuous electroencephalographic recordings were performed in rats during pMCAo.
    Summary · context
    Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred.
    Summary · context
    Control rats received pMCAo and saline treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.